Meet Our Team

Tim Gutwald

Partner
Connect on LinkedIn 

Tim Gutwald is a solutions-oriented attorney who helps healthcare companies grow with confidence while navigating complex legal and regulatory landscapes. As a Partner at Elevare Law, he specializes in telemedicine, virtual behavioral health, digital health, and direct-to-consumer care, guiding founders and operators through multi-state expansion and compliance.

Tim brings a rare combination of in-house leadership and firm experience. As a former General Counsel and Chief Compliance Officer for several health tech companies, he understands firsthand how legal guidance impacts day-to-day operations and growth strategy. His background in litigation also equips him to handle employment matters, contract and payor disputes, regulatory investigations and risk mitigation with an eye toward both prevention and resolution.

He brings deep expertise in privacy, security, HIPAA, and tracking technologies, having worked with clients ranging from early-stage startups to national health systems. Before joining Elevare, he helped a telepsychiatry company  scale its presence from 12 to 40+ states with a 20x increase in revenue. 

Clients trust Tim not just for his sharp legal mind, but for his ability to make complex issues feel manageable - and to show up like part of the team when it counts most. Clients appreciate that Tim provides clear, straightforward advice and works with them to find creative solutions to problems instead of saying “no.”

Tim earned his law degree from Michigan State University College of Law (magna cum laude) and holds an undergraduate degree from Kalamazoo College.

Based in Grand Rapids, Michigan, Tim lives with his wife, five children, a dog, and a cat. Outside of work, you can find him coaching youth sports, cheering on his favorite soccer teams ("Come on United!"), watching medical dramas, and reading history and philosophy books.

Licensed In: Michigan

Check out these blogs written by 

Tim Gutwald

Legal + Regulatory
November 12, 2026
The Peptide Gold Rush Just Got a Rulebook. Sort Of.
Back in July we wrote that the Pharmacy Compounding Advisory Committee had recommended six peptides for the Section 503A Bulks List, and that a recommendation is a milestone rather than a change in the law. The other shoe has now dropped, though not from the direction most people were watching and not in the form most people expected.
Legal + Regulatory
July 31, 2026
The Peptide Gold Rush is Almost Here - And the FDA Just Overruled Its Own Scientists
Back in April, we asked whether you were ready for the peptide gold rush. The answer just got a lot more urgent. This month, an FDA advisory committee broke with the agency’s own scientists and voted to move six popular peptides one big step toward the compounding market.
Legal + Regulatory
June 30, 2026
One Brief, Two Settlements, $6 Million: California's CPOM Trend is Real Now
At the start of May, we warned that the California Attorney General’s Brief in Art Center Holdings vs. MCE was a warning for healthcare companies structured as an MSO/PC. At the end of May, we told you that California was moving from warning to enforcement.
Legal + Regulatory
May 18, 2026
Using Ambient AI Scribes in Healthcare: Consent, Privacy, and Compliance Lessons from the Sharp HealthCare, Sutter Health, and MemorialCare Lawsuits
In an effort to ease the workload of providers and address provider burnout, health systems and medical groups have turned to ambient AI scribe tools. One study found a 21% adoption rate while industry estimates put the adoption rate at 25-35%. As with any technology, implementing AI scribes is not without risk. Two recent class action lawsuits against Sharp HealthCare, Sutter Health, and MemorialCare highlight exactly what is at stake and provide lessons on how healthcare providers can roll out AI scribe tools in a compliant way.
Legal + Regulatory
May 7, 2026
The California AG Just Told You Which MSO-PC Contracts Are a Problem
"Wait—does this mean our continuity agreement is illegal?"
Legal + Regulatory
April 13, 2026
Are You Ready For The Peptide Gold Rush?
Whether it’s Robert Kennedy, Jr. on the Joe Rogan podcast, Martin Shkreli debating Superpower’s Max Marchione, the New York Times, Wall Street Journal here, here, and here, or FDA warning letters, it seems like everybody is talking about peptides. After years of murmurs, grey markets and FDA warning letters it seems like the peptide gold rush is upon us.